Video

Dr. Burnham on Closing the Gap in Health Disparities in Prostate Cancer

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

Leanne Burnham, PhD, postdoctoral fellow, Division of Health Equities, City of Hope, discusses the need to close the gap in health disparities, in prostate cancer.

Health disparities are an ongoing problem in the United States, but more clinical trials ​are being designed to increase diversity in patient populations, Burnham says. At City of Hope, the PARP inhibitor talazoparib (Talzenna) is being evaluated in an ongoing trial specifically in African American, European American, and Asian American men with prostate cancer, Burnham explains.

The goal of the study is to observe any clinically meaningful differences between how these patient subgroups respond to talazoparib based on androgen receptor trinucleotide repeats, Burnham continues. It is understood that ancestry determines how long these repeat links are, Burnham says. Additionally, an inverse correlation between androgen receptor, trinucleotide repeats, and prostate cancer outcomes has been observed, Burnham adds. By looking at talazoparib, the results of the study may yield insight into how to use diversity in a clinical trial in real time, Burnham concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity